Compare Recursion Pharmaceuticals Inc (RXRX) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Snap Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while Snap Inc trades at $4.58 (market cap $7.67B). The key difference: Snap Inc is far larger — about 5× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RXRX | SNAP | |
|---|---|---|
Market Cap | $1.53B | $7.67B |
Sector | Health | Media |
52-Week High | $6.79 | $10.35 |
52-Week Low | $2.84 | $3.93 |
Enterprise Value | $946.50M | $9.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
